The US-Iran war and the blockade of the Hormuz Strait triggered more than a spike in oil prices — it set off an industrial transmission chain running from energy through petrochemicals, green technology, and pharmaceutical R&D. When Japanese chemical manufacturers turned to China for naphtha-derived feedstocks, when Europe confronted the reality of 90%+ dependence on Chinese green-tech components, and when the UK drug regulator began accepting Chinese clinical trial data, a structural picture emerged: China is becoming an industrial hub that cannot be bypassed — not because it moved aggressively, but because the Hormuz blockade left the global supply chain no alternative.
Naphtha Cutoff — A Systemic Crisis for Japan's Chemical Industry
More than 80% of Japan's naphtha demand is supplied by the Middle East. The actual blockade of the Hormuz Strait severed this lifeline. The consequence was not a simple raw-material price hike, but cascading production stoppages:
Ethylene production facilities across Japan were forced to reduce output, operating at minimum levels just to keep the supply chain from collapsing. Naphtha downstream products — ethylene, propylene, butadiene, and other basic chemicals — plummeted, cascading into polyethylene (food packaging, detergent containers), polystyrene (food trays, home appliance parts), butadiene (tire feedstock), and the entire downstream manufacturing ecosystem.
Demand does not disappear — it relocates. Japanese manufacturers discovered that the only supplier capable of replacing naphtha-based chemicals from the Middle East was China.
(Nikkei, April 29 report)
- High-density polyethylene (plastic bags, food containers): 2.7× year-on-year in March
- Polystyrene (food trays, appliance parts): up 76% year-on-year
- Major plastic raw materials overall: up 27% year-on-year
- Butadiene (tire feedstock): imported from China for the first time since 2021, reaching 1.97 million kg in March
- Xylene mixture (paint thinner): imported from China for the first time in 6.5 years
More critically, this is not simply a matter of "buying more." For certain basic chemicals — butadiene is a prime example — there is virtually no non-Chinese alternative supply. Japan's chemical industry shift carries the weight of a systemic re-anchoring. As Nikkei observed, Japanese chemical manufacturers are no longer facing an emergency procurement problem — they are confronting a geographic re-anchoring of the industrial supply chain.
There aren't enough food containers. Even the ink used to print names, expiration dates, and allergen information onto those containers is running out. — Baorong Wanwu Henghe Shui, citing ANN News Japan
Europe's Green-Tech Vulnerability — The 98% Solar Panel Anxiety
If Japan's crisis is about basic chemical feedstocks, Europe's vulnerability lies at the heart of its energy transition: green technology.
Michael Collins, former Deputy Head of the UK Cabinet Office's National Security Strategy, authored a report warning that Europe's dependence on China for green technology has reached an unsettling level:
- Solar panels: 98% from China
- Lithium-ion batteries: 88% from China
- Inverters (critical for renewable grid integration): 61% from China
The report further notes that the defense sector and the green-tech industry share many of the same components and manufacturing techniques — meaning that, as the Hormuz crisis reshapes the global energy landscape, Europe's military-industrial base is also indirectly deepening its dependence on Chinese supply chains.
Solar panel manufacturing shares process pathways with military photovoltaic systems; bottlenecks in lithium battery capacity directly affect the conversion potential of EV batteries for defense applications. Europe is not making a choice between "clean energy" and "defense autonomy" — when the supply chain is this concentrated, the two share the same risk exposure.
An Institutional Window Opens — UK Drug Regulator Accepts Chinese Clinical Data
Beyond chemicals and green technology, a barrier in another domain is loosening.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced that it will accept more data from Chinese clinical trials to accelerate new drug approvals. While the UK has no comprehensive plan yet to fully adopt Chinese data, the remarks by MHRA Chief Executive Dr. June Raine are worth noting:
"We have now reached a stage where, for Western countries like ours, continuing with a strategy of not accepting Chinese data… is simply not viable. In the end, it would only mean missing out on some of the most promising innovative drug development opportunities."
This contrasts sharply with the United States, which is tightening its technology pipeline to China. The UK is choosing to open a window. The intensifying global resource competition triggered by the Hormuz crisis is forcing countries to recalculate the cost of "institutional barriers": shutting out Chinese data and technology is only viable when sufficient alternatives exist. When rising energy and raw-material prices squeeze R&D budgets, the luxury of "keeping the door closed" becomes unaffordable.
Structural "Unbypassability" — Three Nested Layers
Connecting the three threads reveals a three-layer nested structure:
- Layer 1 (Japan's chemicals): Supply cutoff → scarcity-driven necessity. The Hormuz blockade directly severed the naphtha supply, leaving Japan no choice but to turn to China. This is the hardest constraint, immune to policy or ideology.
- Layer 2 (Europe's green tech): Existing dependence → cost-locked inertia. Europe's green-energy transition path was built on "Chinese supply" long before the crisis. No physical replacement exists in the short to medium term. The Hormuz crisis merely amplified the exposure of this dependence.
- Layer 3 (UK pharma regulation): Institutional barrier loosening → a structural door opens. Unlike the first two layers, the loosening of pharmaceutical regulation is not a physical constraint but an institutional choice — demonstrating that the crisis is forcing policymakers to reweight "institutional autonomy" against "efficiency priority."
The common feature across all three layers: China is not the party actively "squeezing" others — it is being pushed into a hub position by a global supply chain in crisis. This structural posture of "forced dependence" is both a testament to China's manufacturing capacity and a new exposure to geopolitical risk — if the global situation eases or alternative supply sources mature, these dependencies could be repoliticized.
A Parallel Mirror — US Chip Sanctions on China
An interesting counterpoint to the three threads above is the latest escalation in US chip sanctions against China:
The US Department of Commerce ordered a halt to equipment supply for Hua Hong Semiconductor. Sima Pingbang's analytical framework: US companies have irreversible dependence on the Chinese market; Chinese supply chains will not break, only adjust; DeepSeek-V4's adaptation to Huawei's Ascend platform validates China's "hardware-software parallel" systemic competition.
The US is trying to create a narrative of "China cannot be relied upon" in the semiconductor space, while at the very same time the entire world is being pushed by the Hormuz crisis into the reality of "having no choice but to rely on China" in chemicals and green technology. These two directions — "decoupling from China" and "forced dependence on China" — coexist in parallel. This is not a contradiction in policy but a reflection of the asymmetry of globalization's depth: the US can push decoupling in cutting-edge AI chips, but in basic chemicals, green energy, and pharmaceutical R&D — sectors that permeate the capillaries of daily industry — the cost of decoupling is too high to bear.